Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• (untitled)1 passage
• A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators.1 passage
• A review of psychosocial factors and personality in the treatment of obstructive sleep apnoea.1 passage
• A role for club cells in smoking-associated lung adenocarcinoma.1 passage
• A scoping review of palliative care outcome measures in interstitial lung disease.1 passage
• A systematic review and meta-analysis of complementary and alternative medicine in asthma.1 passage
• A systematic review of overlapping microRNA patterns in systemic sclerosis and idiopathic pulmonary fibrosis.1 passage
• A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults.1 passage
• ARDS: challenges in patient care and frontiers in research.1 passage
• Acellular human lung scaffolds to model lung disease and tissue regeneration.1 passage
• Acute decompensated pulmonary hypertension.1 passage
• Acute exacerbations of progressive-fibrosing interstitial lung diseases.1 passage
• Acute high-altitude sickness.1 passage
• Acute respiratory distress syndrome.1 passage
• Adipose tissue as a key player in obstructive sleep apnoea.1 passage
• Advanced medical interventions in pleural disease.1 passage
• Advanced pulmonary arterial hypertension: mechanical support and lung transplantation.1 passage
• Advances in asthma pathophysiology: stepping forward from the Maurizio Vignola experience.1 passage
• Advances in pleural infection and malignancy.1 passage
• Advances in target therapy in lung cancer.1 passage
• Adverse childhood experience and asthma onset: a systematic review.1 passage
• Airway granulation response to lung-implantable medical devices: a concise overview.1 passage
• Airway mechanical compression: its role in asthma pathogenesis and progression.1 passage
• Alveolar proteinosis of genetic origins.1 passage
• An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan.1 passage
• An official American Thoracic Society/European Respiratory Society statement: research questions in COPD.1 passage
• Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.1 passage
• Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment.1 passage
• Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review.1 passage
• Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.1 passage
• Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review.1 passage
• Artificial intelligence in pulmonary medicine: computer vision, predictive model and COVID-19.1 passage
• Artificial intelligence in thoracic surgery: past, present, perspective and limits.1 passage
• Association between morning symptoms and physical activity in COPD: a systematic review.1 passage
• Asthma in childhood.1 passage
• Asthma-COPD overlap: current understanding and the utility of experimental models.1 passage
• Awake prone positioning for hypoxaemic respiratory failure: past, COVID-19 and perspectives.1 passage
• BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?1 passage
• Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis.1 passage
• Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.1 passage
• Bariatric surgery: a potential cure for asthma?1 passage
• Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions.1 passage
• Beyond a single pathway: combination therapy in pulmonary arterial hypertension.1 passage
• Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA.1 passage
• Birt-Hogg-Dubé syndrome.1 passage
• Breath analysis of cancer in the present and the future.1 passage
• Breathing fresh air into respiratory research with single-cell RNA sequencing.1 passage
• Bronchial epithelium in children: a key player in asthma.1 passage
• Bronchiectasis: a case-based approach to investigation and management.1 passage
• Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature.1 passage
• Bronchoscopic intratumoural therapies for non-small cell lung cancer.1 passage
• Bronchoscopic management of asthma, COPD and emphysema.1 passage
• Bronchoscopic treatment of inoperable nonsmall cell lung cancer.1 passage
• C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis.1 passage
• CD81 passage
• CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways.1 passage
• COPD and acute myocardial infarction.1 passage
• COPD beyond proximal bronchial obstruction: phenotyping and related tools at the bedside.1 passage
• COPD in individuals with the PiMZ alpha-1 antitrypsin genotype.1 passage
• COPD stands for complex obstructive pulmonary disease.1 passage
• COVID-19 and COPD: a narrative review of the basic science and clinical outcomes.1 passage
• COVID-19 pneumonia: pathophysiology and management.1 passage
• Cadmium in tobacco smokers: a neglected link to lung disease?1 passage
• Can asthmatic subjects dive?1 passage
• Cancer-associated thrombosis: the when, how and why.1 passage
• Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency.1 passage
• Cardiovascular disease and COPD: dangerous liaisons?1 passage
• Cell therapy for lung disease.1 passage
• Cell-derived microparticles and the lung.1 passage
• Cellular interactions in the pathogenesis of interstitial lung diseases.1 passage
• Cellular mechanisms underlying steroid-resistant asthma.1 passage
• Central sleep apnoea and periodic breathing in heart failure: prognostic significance and treatment options.1 passage
• Challenges in pulmonary hypertension: managing the unexpected.1 passage
• Chaotic activation of developmental signalling pathways drives idiopathic pulmonary fibrosis.1 passage
• Chitotriosidase: a marker and modulator of lung disease.1 passage
• Chronic cough: new insights and future prospects.1 passage
• Chronic interstitial lung disease in children.1 passage
• Chronic lung diseases: prospects for regeneration and repair.1 passage
• Chronic thromboembolic pulmonary hypertension: a distinct disease entity.1 passage
• Clinical care for primary ciliary dyskinesia: current challenges and future directions.1 passage
• Clinical phenotyping: role in treatment decisions in sarcoidosis.1 passage
• Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis.1 passage
• Clinically relevant subgroups in COPD and asthma.1 passage
• Coagulation and anticoagulation in idiopathic pulmonary fibrosis.1 passage
• Coinfection with1 passage
• Community-acquired pneumonia in critically ill very old patients: a growing problem.1 passage
• Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue.1 passage
• Comorbidities in interstitial lung diseases.1 passage
• Contemporary issues in the implementation of lung cancer screening.1 passage
• Control of asthma in real life: still a valuable goal?1 passage
• Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?1 passage
• Cough in idiopathic pulmonary fibrosis.1 passage
• Cough symptom severity in patients with refractory or unexplained chronic cough: a systematic survey and conceptual framework.1 passage
• Crosslink bio-adhesives for bronchoscopic lung volume reduction: current status and future direction.1 passage
• Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease.1 passage
• Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.1 passage
• Current and new challenges in occupational lung diseases.1 passage
• Current developments and future directions in COPD.1 passage
• Current developments and future directions in respiratory physiotherapy.1 passage
• Current evidence for COVID-19 therapies: a systematic literature review.1 passage
• Current opinions for the management of asthma associated with ear, nose and throat comorbidities.1 passage
• Cyst-related primary lung malignancies: an important and relatively unknown imaging appearance of (early) lung cancer.1 passage
• Cystic fibrosis-related diabetes and lung disease: an update.1 passage
• Defining a role for exercise training in the management of asthma.1 passage
• Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis.1 passage
• Design of pulmonary rehabilitation programmes during acute exacerbations of COPD: a systematic review and network meta-analysis.1 passage
• Desquamative interstitial pneumonia: a systematic review of its features and outcomes.1 passage
• Development and clinical translation of tubular constructs for tracheal tissue engineering: a review.1 passage
• Development of a simple binary response questionnaire to identify airflow obstruction in a smoking population in Argentina.1 passage
• Developments in lung transplantation over the past decade.1 passage
• Developments in radiation techniques for thoracic malignancies.1 passage
• Developments in the management and treatment of pulmonary embolism.1 passage
• Diagnosing α1-antitrypsin deficiency: how to improve the current algorithm.1 passage
• Diagnosis of chronic thromboembolic pulmonary hypertension.1 passage
• Diagnosis of primary ciliary dyskinesia: potential options for resource-limited countries.1 passage
• Diagnostic advances and opportunities in chronic thromboembolic pulmonary hypertension.1 passage
• Diet and exercise in the management of obstructive sleep apnoea and cardiovascular disease risk.1 passage
• Differential diagnosis of granulomatous lung disease: clues and pitfalls: Number 4 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.1 passage
• Diffuse parenchymal lung disease.1 passage
• Direct oral anticoagulants and venous thromboembolism.1 passage
• Discordant diagnostic criteria for pneumonia in COPD trials: a review.1 passage
• Dismantling airway disease with the use of new pulmonary function indices.1 passage
• Dismantling the pathophysiology of asthma using imaging.1 passage
• Does cytoreduction surgery and hyperthermic intrathoracic chemotherapy prolong survival in patients with N0-N1 nonsmall cell lung cancer and malignant pleural effusion?1 passage
• Does the use of inhaled corticosteroids in asthma benefit lung function in the long-term? A systematic review and meta-analysis.1 passage
• Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?1 passage
• Dysfunctional breathing: a review of the literature and proposal for classification.1 passage
• ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases.1 passage
• ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia.1 passage
• ERS/EAACI statement on adherence to international adult asthma guidelines.1 passage
• ERS/ELS/ACCP 2013 international consensus conference nomenclature on inducible laryngeal obstructions.1 passage
• Early diagnosis of COPD: myth or a true perspective.1 passage
• Early origins of lung disease: towards an interdisciplinary approach.1 passage
• Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis.1 passage
• Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities.1 passage
• Effectiveness of interventions for reducing TB incidence in countries with low TB incidence: a systematic review of reviews.1 passage
• Efficacy and safety profile of xanthines in COPD: a network meta-analysis.1 passage
• Emerging role of cardiovascular magnetic resonance imaging in the management of pulmonary hypertension.1 passage
• Endobronchial valves for severe emphysema.1 passage
• Endoplasmic reticulum stress in lung disease.1 passage
• Environmental exposure to pesticides and respiratory health.1 passage
• Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation.1 passage
• Epigenetic mechanisms in pulmonary arterial hypertension: the need for global perspectives.1 passage
• Epigenetics and sarcoidosis.1 passage
• Epithelial cell migration as a potential therapeutic target in early lung cancer.1 passage
• Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience.1 passage
• European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea.1 passage
• Evaluating disease severity in idiopathic pulmonary fibrosis.1 passage
• Exacerbations of COPD.1 passage
• Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms.1 passage
• Exercise training for lung transplant candidates and recipients: a systematic review.1 passage
• Exertional dyspnoea in COPD: the clinical utility of cardiopulmonary exercise testing.1 passage
• Exertional dyspnoea in chronic heart failure: the role of the lung and respiratory mechanical factors.1 passage
• Exertional dyspnoea in interstitial lung diseases: the clinical utility of cardiopulmonary exercise testing.1 passage
• Exertional dyspnoea in obesity.1 passage
• Exertional dyspnoea in pulmonary arterial hypertension.1 passage
• Exertional ventilation/carbon dioxide output relationship in COPD: from physiological mechanisms to clinical applications.1 passage
• Experiences of noninvasive ventilation in adults with hypercapnic respiratory failure: a review of evidence.1 passage
• Exploring the 175-year history of spirometry and the vital lessons it can teach us today.1 passage
• Extracellular matrix remodelling in COPD.1 passage
• Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review.1 passage
• Fibrosing interstitial lung diseases: knowns and unknowns.1 passage
• Fibrotic interstitial lung diseases and air pollution: a systematic literature review.1 passage
• From systems biology to P4 medicine: applications in respiratory medicine.1 passage
• Fully integrating pathophysiological insights in COPD: an updated working disease model to broaden therapeutic vision.1 passage
• Future concepts in bronchodilation for COPD: dual-1 passage
• Future perspectives in pulmonary arterial hypertension.1 passage
• Future treatment for asthma.1 passage
• Genetic disorders of the surfactant system: focus on adult disease.1 passage
• Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.1 passage
• Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.1 passage
• Heritable pulmonary hypertension: from bench to bedside.1 passage
• Hermansky-Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease.1 passage
• Host-microbe interactions in distal airways: relevance to chronic airway diseases.1 passage
• How I manage pulmonary Langerhans cell histiocytosis.1 passage
• How bacteria hack the matrix and dodge the bullets of immunity.1 passage
• How best to capture the respiratory consequences of prematurity?1 passage
• How can we minimise the use of regular oral corticosteroids in asthma?1 passage
• How long is too long? A scoping review of health system delays in lung cancer.1 passage
• How should we monitor patients with acute respiratory failure treated with noninvasive ventilation?1 passage
• How to handle oligometastatic disease in nonsmall cell lung cancer.1 passage
• Human pluripotent stem cells for the modelling and treatment of respiratory diseases.1 passage
• Idiopathic inflammatory myopathies and the lung.1 passage
• Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night.1 passage
• Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences.1 passage
• Imaging the heart in pulmonary hypertension: an update.1 passage
• Immune checkpoints in chronic obstructive pulmonary disease.1 passage
• Immune reconstitution inflammatory syndrome associated with pulmonary pathogens.1 passage
• Immunological and toxicological risk assessment of e-cigarettes.1 passage
• Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease.1 passage
• Impact of ageing and pregnancy on the minute ventilation/carbon dioxide production response to exercise.1 passage
• Impact of latent tuberculosis infection on health and wellbeing: a systematic review and meta-analysis.1 passage
• Impact of the financial crisis on COPD burden: Greece as a case study.1 passage
• Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome.1 passage
• Indoor mould exposure, asthma and rhinitis: findings from systematic reviews and recent longitudinal studies.1 passage
• Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.1 passage
• Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens.1 passage
• Influenza vaccination: protecting the most vulnerable.1 passage
• Informal caregivers of patients with COPD: Home Sweet Home?1 passage
• Inhaler technique: does age matter? A systematic review.1 passage
• Innate immunity is a key factor for the resolution of inflammation in asthma.1 passage
• Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.1 passage
• Integration of interventional bronchoscopy in the management of lung cancer.1 passage
• Interdisciplinary multimodality management of stage III nonsmall cell lung cancer.1 passage
• Interpreting risk reduction in clinical trials for pulmonary arterial hypertension.1 passage
• Intersections of lung progenitor cells, lung disease and lung cancer.1 passage
• Interstitial lung disease in lysosomal storage disorders.1 passage
• Interstitial lung disease in systemic sclerosis: where do we stand?1 passage
• Is bronchiectasis really a disease?1 passage
• Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma?1 passage
• Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?1 passage
• KRAS oncogene in lung cancer: focus on molecularly driven clinical trials.1 passage
• LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment.1 passage
• Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations.1 passage
• Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections.1 passage
• Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?1 passage
• Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.1 passage
• Long-term experience in the treatment of α1-antitrypsin deficiency: 25 years of augmentation therapy.1 passage
• Long-term macrolides in diffuse interstitial lung diseases.1 passage
• Lung ageing and COPD: is there a role for ageing in abnormal tissue repair?1 passage
• Lung cancer is also a hereditary disease.1 passage
• Lung clearance index: assessment and utility in children with asthma.1 passage
• Lung complications of Sjogren syndrome.1 passage
• Lung imaging.1 passage
• Lung involvement in monogenic interferonopathies.1 passage
• Lung nodules: size still matters.1 passage
• Lung regeneration: implications of the diseased niche and ageing.1 passage
• Lung segmentectomy: does it offer a real functional benefit over lobectomy?1 passage
• Lung transplantation for interstitial lung disease.1 passage
• Macrophage adaptation in airway inflammatory resolution.1 passage
• Malignant pleural effusion: from bench to bedside.1 passage
• Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.1 passage
• Management of anticoagulant and antiplatelet therapy in patients undergoing interventional pulmonary procedures.1 passage
• Management of antithrombotic agents in patients undergoing flexible bronchoscopy.1 passage
• Management of asthma exacerbations in the paediatric population: a systematic review.1 passage
• Management of chronic respiratory complications in children and adolescents with sickle cell disease.1 passage
• Management of insomnia in sleep disordered breathing.1 passage
• Management of pulmonary toxicity associated with immune checkpoint inhibitors.1 passage
• Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study.1 passage
• Management of sarcoidosis in clinical practice.1 passage
• Management of suspected monogenic lung fibrosis in a specialised centre.1 passage
• Management of tracheo-oesophageal fistula in adults.1 passage
• Managing adult Fontan patients: where do we stand?1 passage
• Matrix abnormalities in pulmonary fibrosis.1 passage
• Measuring airway clearance outcomes in bronchiectasis: a review.1 passage
• Measuring pulmonary function in COPD using quantitative chest computed tomography analysis.1 passage
• Mechanisms, measurement and management of exertional dyspnoea in asthma: Number 5 in the Series "Exertional dyspnoea" Edited by Pierantonio Laveneziana and Piergiuseppe Agostoni.1 passage
• Mediastinal tumours and pseudo-tumours: a comprehensive review with emphasis on multidisciplinary approach.1 passage
• Medical management of chronic thromboembolic pulmonary hypertension.1 passage
• Meta-analysis on short-term exposure to ambient ultrafine particles and respiratory morbidity.1 passage
• Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.1 passage
• Metabolism in tumour-associated macrophages: a1 passage
• Metabolomics and microbiome profiling as biomarkers in obstructive sleep apnoea: a comprehensive review.1 passage
• Minimal clinically important difference for asthma endpoints: an expert consensus report.1 passage
• Minute ventilation/carbon dioxide production in chronic heart failure.1 passage
• Minute ventilation/carbon dioxide production in congenital heart disease.1 passage
• Minute ventilation/carbon dioxide production in patients with dysfunctional breathing.1 passage
• Mitochondrial dysfunction in lung ageing and disease.1 passage
• Monitoring asthma in childhood.1 passage
• Monitoring asthma in childhood: lung function, bronchial responsiveness and inflammation.1 passage
• Monitoring asthma in childhood: management-related issues.1 passage
• Monitoring asthma in childhood: symptoms, exacerbations and quality of life.1 passage
• Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments.1 passage
• Multidisciplinary evaluation of interstitial lung diseases: current insights: Number 1 in the Series "Radiology" Edited by Nicola Sverzellati and Sujal Desai.1 passage
• Multiple cystic lung disease.1 passage
• Nasal high flow therapy: a novel treatment rather than a more expensive oxygen device.1 passage
• National and regional asthma programmes in Europe.1 passage
• Natural experiments and large databases in respiratory and cardiovascular disease.1 passage
• Natural variability in the disease course of SSc-ILD: implications for treatment.1 passage
• Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives.1 passage
• New bronchoscopic treatment modalities for patients with chronic bronchitis.1 passage
• New developments in locally advanced nonsmall cell lung cancer.1 passage
• New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis.1 passage
• New organisation for follow-up and assessment of treatment efficacy in sleep apnoea.1 passage
• Non-sleepy obstructive sleep apnoea: to treat or not to treat?1 passage
• Noninfectious pulmonary complications of haematopoietic stem cell transplantation.1 passage
• Noninvasive ventilation in acute respiratory failure: which recipe for success?1 passage
• Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.1 passage
• Nutritional advances in patients with respiratory diseases.1 passage
• Obesity hypoventilation syndrome.1 passage
• Obstructive sleep apnoea in acute coronary syndrome.1 passage
• Occupational exposure to pesticides and respiratory health.1 passage
• Oxygen therapy for interstitial lung disease: a systematic review.1 passage
• Oxygen, the lung and the diver: friends and foes?1 passage
• PET/CT in nononcological lung diseases: current applications and future perspectives.1 passage
• Paediatric lung imaging: the times they are a-changin'.1 passage
• Paediatric respiratory infections.1 passage
• Palliative care in pulmonary arterial hypertension: an underutilised treatment.1 passage
• Particulate matter and the airway epithelium: the special case of the underground?1 passage
• Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled.1 passage
• Patient engagement and self-management in pulmonary arterial hypertension.1 passage
• Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?1 passage
• Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases.1 passage
• Performance of alternative COPD case-finding tools: a systematic review and meta-analysis.1 passage
• Personalised medicine for nonsmall cell lung cancer.1 passage
• Personalised medicine in asthma: from curative to preventive medicine.1 passage
• Personalised medicine in asthma: time for action: Number 1 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.1 passage
• Personalised medicine in interstitial lung diseases: Number 6 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.1 passage
• Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment.1 passage
• Personalised pulmonary rehabilitation in COPD.1 passage
• Personalising airway clearance in chronic lung disease.1 passage
• Perspectives for systems biology in the management of tuberculosis.1 passage
• Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.1 passage
• Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension.1 passage
• Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential.1 passage
• Physiology of the lung in idiopathic pulmonary fibrosis.1 passage
• Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.1 passage
• Platelets: a potential role in chronic respiratory diseases?1 passage
• Post-intubation subglottic stenosis: aetiology at the cellular and molecular level.1 passage
• Practical considerations for therapies targeting the prostacyclin pathway.1 passage
• Pre-operative screening for obstructive sleep apnoea.1 passage
• Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.1 passage
• Precision medicine in COPD: where are we and where do we need to go?1 passage
• Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research.1 passage
• Precision medicine is coming to town: personalising home ventilatory equipment in COPD patients with chronic hypercapnic respiratory failure.1 passage
• Prediction models for exacerbations in patients with COPD.1 passage
• Pregnancy in pulmonary arterial hypertension.1 passage
• Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.1 passage
• Prevalence and outcomes of pulmonary hypertension after percutaneous closure of atrial septal defect: a systematic review and meta-analysis.1 passage
• Prevalence of α1 passage
• Primary lung neoplasms presenting as multiple synchronous lung nodules.1 passage
• Prioritising children and adolescents in the tuberculosis response of the WHO European Region.1 passage
• Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis.1 passage
• Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review.1 passage
• Prognostic considerations of the new World Health Organization classification of lung adenocarcinoma.1 passage
• Prognostic factors in chronic hypersensitivity pneumonitis.1 passage
• Protecting healthcare workers from SARS-CoV-2 infection: practical indications.1 passage
• Pulmonary alveolar microlithiasis.1 passage
• Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide.1 passage
• Pulmonary arterial hypertension: tailoring treatment to risk in the current era.1 passage
• Pulmonary arterial hypertension: the burden of disease and impact on quality of life.1 passage
• Pulmonary capillary haemangiomatosis: a distinct entity?1 passage
• Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer.1 passage
• Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension.1 passage
• Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension.1 passage
• Pulmonary function testing in children's interstitial lung disease.1 passage
• Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease.1 passage
• Pulmonary granulomatosis of genetic origin.1 passage
• Pulmonary hypertension and chronic lung disease: where are we headed?1 passage
• Pulmonary hypertension associated with neurofibromatosis type 1.1 passage
• Pulmonary hypertension in patients with chronic myeloproliferative disorders.1 passage
• Pulmonary hypertension in systemic sclerosis: different phenotypes.1 passage
• Pulmonary hypertension phenotypes in patients with systemic sclerosis.1 passage
• Pulmonary hypertension.1 passage
• Pulmonary hypertension: the importance of correctly diagnosing the cause.1 passage
• Pulmonary hypertensive vasculopathy in parenchymal lung diseases and/or hypoxia: Number 1 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.1 passage
• Pulmonary manifestations of Sjögren's syndrome.1 passage
• Pulmonary vascular and cardiac impairment in interstitial lung disease.1 passage
• Pulmonary vascular development in congenital diaphragmatic hernia.1 passage
• Radio(chemo)therapy in locally advanced nonsmall cell lung cancer.1 passage
• Recent advances in mechanical ventilation in patients with acute respiratory distress syndrome.1 passage
• Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.1 passage
• Recent developments in advanced diagnostic bronchoscopy.1 passage
• Recent developments in the treatment of small cell lung cancer.1 passage
• Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.1 passage
• Receptor for advanced glycation end-products and environmental exposure related obstructive airways disease: a systematic review.1 passage
• Recycling plastic: diagnosis and management of plastic bronchitis among adults.1 passage
• Respiratory muscle senescence in ageing and chronic lung diseases.1 passage
• Respiratory viral infection: a potential "missing link" in the pathogenesis of COPD.1 passage
• Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment.1 passage
• Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management.1 passage
• Right heart catheterisation: best practice and pitfalls in pulmonary hypertension.1 passage
• Risk assessment in pulmonary arterial hypertension.1 passage
• Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis.1 passage
• Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit.1 passage
• Role of imaging in progressive-fibrosing interstitial lung diseases.1 passage
• Sarcopenia in COPD: a systematic review and meta-analysis.1 passage
• Schistosomiasis-associated pulmonary arterial hypertension: a systematic review.1 passage
• Screening for COPD: the gap between logic and evidence.1 passage
• Screening for pulmonary arterial hypertension in systemic sclerosis.1 passage
• Second-line combination therapies in nonsmall cell lung cancer without known driver mutations.1 passage
• Sensors for detecting pulmonary diseases from exhaled breath.1 passage
• Severe T2-high asthma in the biologics era: European experts' opinion.1 passage
• Severe idiopathic pulmonary fibrosis: what can be done?1 passage
• Sex and gender in asthma.1 passage
• Sex and gender in interstitial lung diseases.1 passage
• Sex and gender in pulmonary arterial hypertension.1 passage
• Sex and gender in respiratory physiology.1 passage
• Sex differences in obstructive sleep apnoea.1 passage
• Shared epithelial pathways to lung repair and disease.1 passage
• Shared mechanisms of multimorbidity in COPD, atherosclerosis and type-2 diabetes: the neutrophil as a potential inflammatory target.1 passage
• Short- and long-term effects of diving on pulmonary function.1 passage
• Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety.1 passage
• Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials.1 passage
• Should I stay or should I go? COPD and air travel.1 passage
• Should lung biopsies be performed in patients with severe asthma?1 passage
• Sleep apnoea and driving risk: the need for regulation.1 passage
• Sleep apnoea.1 passage
• Sleep disordered breathing in childhood.1 passage
• Sleep in chronic respiratory disease: COPD and hypoventilation disorders.1 passage
• Smoking and interstitial lung diseases.1 passage
• Sphingolipids in COPD.1 passage
• Sports related to drowning.1 passage
• Sports-related lung injury during breath-hold diving.1 passage
• State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances.1 passage
• Structure and function of small airways in asthma patients revisited.1 passage
• Subglottic secretion drainage for preventing ventilator-associated pneumonia: an overview of systematic reviews and an updated meta-analysis.1 passage
• Sustained inflations and avoiding mechanical ventilation to prevent death or bronchopulmonary dysplasia: a meta-analysis.1 passage
• Systematic review and meta-analysis of residential radon and lung cancer in never-smokers.1 passage
• Systematic review of drug effects in humans and models with surfactant-processing disease.1 passage
• Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD.1 passage
• Systems medicine advances in interstitial lung disease.1 passage
• TB research and innovation in Latin America.1 passage
• Targeted screening programmes in COPD: how to identify individuals with α1-antitrypsin deficiency.1 passage
• Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis.1 passage
• Telemedicine in the diagnosis and treatment of sleep apnoea.1 passage
• The European Respiratory Review: farewell from the editor with confidence for the future.1 passage
• The ageing lung under stress.1 passage
• The air of Europe: where are we going?1 passage
• The biology of pulmonary exacerbations in bronchiectasis.1 passage
• The broad spectrum of lung diseases in primary antibody deficiencies.1 passage
• The changing landscape of chronic thromboembolic pulmonary hypertension management.1 passage
• The changing treatment landscape in idiopathic pulmonary fibrosis.1 passage
• The clinical value of cardiopulmonary exercise testing in the modern era.1 passage
• The consequence of matrix dysfunction on lung immunity and the microbiome in COPD.1 passage
• The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis.1 passage
• The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects.1 passage
• The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis.1 passage
• The effects of lung volume reduction treatment on diffusing capacity and gas exchange.1 passage
• The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review.1 passage
• The efficacy of bedside chest ultrasound: from accuracy to outcomes.1 passage
• The efficacy of immune checkpoint inhibitors in thoracic malignancies.1 passage
• The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype.1 passage
• The exposome concept: a challenge and a potential driver for environmental health research.1 passage
• The fog, the attractive and the addictive: pulmonary effects of vaping with a focus on the contribution of each major vaping liquid constituent.1 passage
• The frequent and underrecognised co-occurrence of acute exacerbated COPD and depression warrants screening: a systematic review.1 passage
• The future of bronchodilation: looking for new classes of bronchodilators.1 passage
• The genetics of interstitial lung diseases.1 passage
• The heterogeneity of lung macrophages in the susceptibility to disease.1 passage
• The impact of outdoor air pollution on COVID-19: a review of evidence from1 passage
• The integrated stress response in pulmonary disease.1 passage
• The lung in amyloidosis.1 passage
• The management of benign non-infective pleural effusions.1 passage
• The measurement properties of tests and tools used in cystic fibrosis studies: a systematic review.1 passage
• The microbiome in bronchiectasis.1 passage
• The multidisciplinary approach in the diagnosis of idiopathic pulmonary fibrosis: a patient case-based review.1 passage
• The multifaceted roles of the matrikine Pro-Gly-Pro in pulmonary health and disease.1 passage
• The pathophysiology of chronic thromboembolic pulmonary hypertension.1 passage
• The prevalence and related factors of fatigue in patients with COPD: a systematic review.1 passage
• The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis.1 passage
• The radiological diagnosis of bronchiectasis: what's in a name?1 passage
• The respiratory microbiome and nontuberculous mycobacteria: an emerging concern in human health.1 passage
• The role of cardiopulmonary exercise tests in pulmonary arterial hypertension.1 passage
• The role of high-resolution computed tomography in the follow-up of diffuse lung disease: Number 2 in the Series "Radiology" Edited by Nicola Sverzellati and Sujal Desai.1 passage
• The role of macrophages in interstitial lung diseases: Number 3 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.1 passage
• The role of moxifloxacin in tuberculosis therapy.1 passage
• The role of mucin 1 in respiratory diseases.1 passage
• The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review.1 passage
• The therapy of idiopathic pulmonary fibrosis: what is next?1 passage
• The time-controlled adaptive ventilation protocol: mechanistic approach to reducing ventilator-induced lung injury.1 passage
• The use of chest magnetic resonance imaging in interstitial lung disease: a systematic review.1 passage
• Therapeutic bronchoscopy for central airway diseases.1 passage
• Therapeutic strategies in pneumonia: going beyond antibiotics.1 passage
• Therapeutic targeting of metabolic alterations in acute respiratory distress syndrome.1 passage
• Thoracic involvement and imaging patterns in IgG4-related disease.1 passage
• Thoracic involvement in generalised lymphatic anomaly (or lymphangiomatosis).1 passage
• Thoracic ultrasound competence for ultrasound-guided pleural procedures.1 passage
• Thoracic ultrasound in the modern management of pleural disease.1 passage
• Thymic tumours and their special features.1 passage
• Tobacco control in Europe: a policy review.1 passage
• Training in interventional pulmonology: the European and US perspective.1 passage
• Treating restless legs syndrome in the context of sleep disordered breathing comorbidity.1 passage
• Tuberculosis and lung damage: from epidemiology to pathophysiology.1 passage
• Tuberculosis elimination: where are we now?1 passage
• Tuberous sclerosis complex for the pulmonologist.1 passage
• Tumoral pulmonary hypertension.1 passage
• Ultra-rare cystic disease.1 passage
• Unclassifiable interstitial lung disease: a pathologist's perspective.1 passage
• Under pressure: pulmonary hypertension associated with left heart disease.1 passage
• Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care.1 passage
• Update on biology and management of mesothelioma.1 passage
• Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.1 passage
• Update on oral appliance therapy.1 passage
• Update on recent key publications in lung oncology: picking up speed.1 passage
• Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020).1 passage
• Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease.1 passage
• Use of pedometers as a tool to promote daily physical activity levels in patients with COPD: a systematic review and meta-analysis.1 passage
• Ventilation/carbon dioxide output relationships during exercise in health.1 passage
• Ventilatory efficiency and its clinical and prognostic value in adults with cystic fibrosis.1 passage
• Ventilatory efficiency in athletes, asthma and obesity.1 passage
• Ventilatory efficiency in pulmonary vascular diseases.1 passage
• Viral infection in community-acquired pneumonia: a systematic review and meta-analysis.1 passage
• Viral infections in wheezing disorders.1 passage
• Volatile organic compounds and risk of asthma and allergy: a systematic review.1 passage
• Waterpipe smoking: a review of pulmonary and health effects.1 passage
• What have we learned from basic science studies on idiopathic pulmonary fibrosis?1 passage
• What people with Down Syndrome can teach us about cardiopulmonary disease.1 passage
• What type of clinical evidence is needed to assess medical devices?1 passage
• When to start and when to stop antifibrotic therapies.1 passage
• Women and COPD: do we need more evidence?1 passage
• α1 passage